HDL-mediated mechanisms of protection in cardiovascular disease

Cardiovascular Research

Volumn 103, Issue 3, 2014, Pages 341-349

  Kontush, Anatol ^a  

^a INSERM   (France)

Author keywords

Atheroprotection; Biological activities; Cardiovascular disease; HDL; Mechanisms

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; MICRORNA; AUTACOID; BIOLOGICAL MARKER; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRAIN; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CELL PROTECTION; CHOLESTEROL TRANSPORT; GENE EXPRESSION REGULATION; GLUCOSE METABOLISM; HEART PROTECTION; HUMAN; INFECTION; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; VASODILATATION; ANIMAL; BLOOD; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; GENETICS; METABOLISM; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROGNOSIS; PROTECTION; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM;

ANIMALS; BIOLOGICAL MARKERS; BRAIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION MEDIATORS; MICRORNAS; OXIDATIVE STRESS; PLATELET ACTIVATION; PROGNOSIS; PROTECTIVE FACTORS; RISK FACTORS; SIGNAL TRANSDUCTION; VASODILATION;

EID: 84905586512     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu147     Document Type: Review

References (182)

1. Chapman MJ. Beyond the statins: New therapeutic perspectives in cardiovascular disease prevention. Cardiovasc Drugs Ther 2005;19:135-139
2. Francis GA. The complexity of HDL. Biochim Biophys Acta 2010;1801:1286-1293
3. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. J. Lipid Res 2009;50:S145-S149
4. Khera AV, Cuchel M, De La Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis.NEngl JMed 2011;364:127-135
5. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: Atherogenic and atheroprotective mechanisms. Nat Rev Cardiol 2011;8:222-232
6. Stein O, Stein Y. Atheroprotective mechanisms of HDL. Atherosclerosis 1999;144: 285-301
7. Nofer JR, Kehrel B, Fobker M, Levkau B, Assmann G, von Eckardstein A. HDL and arteriosclerosis: Beyond reverse cholesterol transport. Atherosclerosis 2002;161:1-16
8. Assmann G, Nofer JR. Atheroprotective effects of high-density lipoproteins. Annu Rev Med 2003;54:321-341
9. Assmann G, Gotto AM Jr. HDL Cholesterol and Protective Factors in Atherosclerosis. Circulation 2004;109: III8-14
10. Navab M, Ananthramaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fonarow GC, Vahabzadeh K, Hama S, Hough G, Kamranpour N, Berliner JA, Lusis AJ, Fogelman AM. The oxidation hypothesis of atherogenesis: The role of oxidized phospholipids and HDL. J Lipid Res 2004;45:993-1007
11. Kontush A, Chapman MJ. Functionally defective HDL: A new therapeutic target at the crossroads of dyslipidemia, inflammation and atherosclerosis. Pharmacol Rev 2006;3: 342-374
12. Gordon SM, Hofmann S, AskewDS, DavidsonWS.High density lipoprotein: Its not just about lipid transport anymore. Trends Endocrinol Metab 2011;22:9-15
13. Lim HY, Thiam CH, Yeo KP, Bisoendial R, Hii CS, McGrath KC, Tan KW, Heather A, Alexander JS, Angeli V. Lymphatic vessels are essential for the removal of cholesterol from peripheral tissues by SR-BI-mediated transport of HDL. Cell Metab 2013;17: 671-684
14. Stukas S, Robert J,Wellington CL. High-Density Lipoproteins and Cerebrovascular Integrity in Alzheimers Disease. Cell Metab 2014;19:574-591
15. von Eckardstein A, Nofer JR, Assmann G. High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport. Arterioscler Thromb Vasc Biol 2001;21:13-27
16. Miller GJ, Miller NE. Plasma-high-density-lipoprotein concentration and development of ischaemic heart-disease. Lancet 1975;1:16-19
17. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 2013;33:1696-1705
18. Kingwell BA, Chapman MJ. Future of high-density lipoprotein infusion therapies: Potential for clinical management of vascular disease. Circulation 2013;128:1112-1121
19. von Eckardstein A, Rohrer L. Transendothelial lipoprotein transport and regulation of endothelial permeability and integrity by lipoproteins. Curr Opin Lipidol 2009;20: 197-205
20. Rohrer L, Ohnsorg PM, Lehner M, Landolt F, Rinninger F, von Eckardstein A. Highdensity lipoprotein transport through aortic endothelial cells involves scavenger receptor BI and ATP-binding cassette transporter G1. Circ Res 2009;104:1142-1150
21. Cavelier C, Rohrer L, von Eckardstein A. ATP-Binding cassette transporter A1 modulates apolipoprotein A-I transcytosis through aortic endothelial cells. Circ Res 2006;99: 1060-1066
22. Rohrer L, Cavelier C, Fuchs S, Schluter MA, VolkerW, von Eckardstein A. Binding, internalization and transport of apolipoprotein A-I by vascular endothelial cells. Biochim Biophys Acta 2006;1761:186-194
23. Rothblat GH, De La Llera-MoyaM, AtgerV, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: Integration of old and new observations provides new insights. J Lipid Res 1999;40:781-796
24. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R. Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-79
25. Oram JF, Lawn RM, Garvin MR,Wade DP. ABCA1 is the cAMP-inducible apolipoprotein receptor that mediates cholesterol secretion from macrophages. J Biol Chem 2000; 275:34508-34511
26. Mott S, Yu L, Marcil M, Boucher B, Rondeau C, Genest J Jr. Decreased cellular cholesterol efflux is acommoncauseof familial hypoalphalipoproteinemia: Role of theABCA1 gene mutations. Atherosclerosis 2000;152:457-468
27. Adorni MP, Zimetti F, Billheimer JT,Wang N, Rader DJ, Phillips MC, Rothblat GH. The roles of different pathways in the release of cholesterol from macrophages. J Lipid Res 2007;48:2453-2462
28. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH. The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res 2009;50:S189-S194
29. Zhao Y, Van Berkel TJ, Van Eck M. Relative roles of various efflux pathways in net cholesterol efflux from macrophage foam cells in atherosclerotic lesions. Curr Opin Lipidol 2010;21:441-453
30. Yvan-Charvet L,Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010;30: 139-143
31. Stefulj J, Panzenboeck U, Becker T, Hirschmugl B, Schweinzer C, Lang I, Marsche G, Sadjak A, Lang U, Desoye G, Wadsack C. Human endothelial cells of the placental barrier efficiently deliver cholesterol to the fetal circulation via ABCA1 and ABCG1. Circ Res 2009;104:600-608
32. Larrede S, Quinn CM, Jessup W, Frisdal E, Olivier M, Hsieh V, Kim M-J, Van Eck M, Couvert P, Carrie A, Giral P, Chapman MJ, Guerin M, Le GoffW. Stimulation of cholesterol efflux by LXR agonists in cholesterol-loaded human macrophages is ABCA1- dependent but ABCG1-independent. Arterioscler Thromb Vasc Biol 2009;29: 1930-1936
33. Burgess B, Naus K, Chan J, Hirsch-Reinshagen V, Tansley G, Matzke L, Chan B, Wilkinson A, Fan J, Donkin J, Balik D, Tanaka T, Ou G, Dyer R, Innis S, McManus B, Lutjohann D,Wellington C. Overexpression of human ABCG1 does not affect atherosclerosis in fat-fed apoE-deficient mice. Arterioscler Thromb Vasc Biol 2008;28: 1731-1737
34. Baldan A, Pei L, Lee R, Tarr P, Tangirala RK,Weinstein MM, Frank J, Li AC, Tontonoz P, Edwards PA. Impaired development of atherosclerosis in hyperlipidemic Ldlr-/- and ApoE-/- mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 2006;26:2301-2307
35. Ranalletta M,Wang N, Han S, Yvan-Charvet L,Welch C, Tall AR. Decreased atherosclerosis in low-density lipoprotein receptor knockout mice transplanted with Abcg1-/- bone marrow. Arterioscler Thromb Vasc Biol 2006;26:2308-2315
36. Out R, HoekstraM, Habets K, Meurs I, deWaard V, Hildebrand RB,Wang Y, Chimini G, Kuiper J, Van Berkel TJ, Van Eck M. Combined deletion of macrophage ABCA1 and ABCG1 leads to massive lipid accumulation in tissue macrophages and distinct atherosclerosis at relatively low plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2008; 28:258-264
37. Out R, Hoekstra M, Meurs I, De Vos P, Kuiper J, Van Eck M, Van Berkel TJC. Total body ABCG1 expression protects against early atherosclerotic lesion development in mice. Arterioscler Thromb Vasc Biol 2007;27:594-599
38. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, RothblatGH, Tall AR, Rader DJ. Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-2224
39. Van Eck M, Pennings M, Hoekstra M, Out R, Van Berkel TJ. Scavenger receptor BI and ATP-binding cassette transporter A1 in reverse cholesterol transport and atherosclerosis. Curr Opin Lipidol 2005;16:307-315
40. Zhang Y, McGillicuddy FC, Hinkle CC, ONeill S, Glick JM, Rothblat GH, Reilly MP. Adipocyte modulation of high-density lipoprotein cholesterol. Circulation 2010;121: 1347-1355
41. Mazzone T. Apolipoprotein E secretion by macrophages: Its potential physiological functions. Curr Opin Lipidol 1996;7:303-307
42. Mazzone T, Reardon C. Expression of heterologous human apolipoprotein E by J774 macrophages enhances cholesterol efflux to HDL3. J Lipid Res 1994;35:1345-1353
43. Zhang WY, Gaynor PM, Kruth HS. Apolipoprotein E produced by human monocytederived macrophages mediates cholesterol efflux that occurs in the absence of added cholesterol acceptors. J Biol Chem 1996;271:28641-28646
44. Ishiguro H, Yoshida H, Major AS, Zhu T, Babaev VR, Linton MF, Fazio S. Retrovirusmediated expression of apolipoprotein A-I in the macrophage protects against atherosclerosis in vivo. J Biol Chem 2001;276:36742-36748
45. Huang Y, Didonato JA, Levison BS, Schmitt D, Li L, Wu Y, Buffa J, Kim T, Gerstenecker GS, Gu X, Kadiyala CS, Wang Z, Culley MK, Hazen JE, Didonato AJ, Fu X, Berisha SZ, Peng D, Nguyen TT, Liang S, Chuang CC, Cho L, Plow EF, Fox PL, Gogonea V, Tang WH, Parks JS, Fisher EA, Smith JD, Hazen SL. An abundant dysfunctional apolipoprotein A1 in human atheroma. Nat Med 2014;20:193-203
46. Krimbou L, Denis M, Haidar B, Carrier M, Marcil M, Genest J Jr. Molecular interactions between apoE and ABCA1: Impact on apoE lipidation. J Lipid Res 2004;45:839-848
47. Chroni A, Nieland TJ, Kypreos KE, Krieger M, Zannis VI. SR-BI mediates cholesterol efflux via its interactions with lipid-bound ApoE. Structural mutations in SR-BI diminish cholesterol efflux. Biochemistry 2005;44:13132-13143
48. MahleyRW, Huang Y,Weisgraber KH. Putting cholesterol in its place: ApoE and reverse cholesterol transport. J Clin Invest 2006;116:1226-1229
49. An S, Jang YS, Park JS, Kwon BM, Paik YK, Jeong TS. Inhibition of acyl-coenzyme A:cholesterol acyltransferase stimulates cholesterol efflux from macrophages and stimulates farnesoid X receptor in hepatocytes. Exp Mol Med 2008;40:407-417
50. Ghosh S, Zhao B, Bie J, Song J. Macrophage cholesteryl ester mobilization and atherosclerosis. Vascul Pharmacol 2010;52:1-10
51. Zhao B, Song J, St Clair RW, Ghosh S. Stable overexpression of human macrophage cholesteryl ester hydrolase results in enhanced free cholesterol efflux from human THP1 macrophages. Am J Physiol Cell Physiol 2007;292:C405-C412
52. Zhao B, Song J,ChowWN,St ClairRW, Rudel LL, Ghosh S. Macrophage-specific transgenic expression of cholesteryl ester hydrolase significantly reduces atherosclerosis and lesion necrosis in Ldlr mice. J Clin Invest 2007;117:2983-2992
53. Dikkers A, Tietge UJ. Biliary cholesterol secretion:morethan a simple ABC.World J Gastroenterol 2010;16:5936-5945
54. Wiersma H, Gatti A, Nijstad N, Oude Elferink RP, Kuipers F, Tietge UJ. Scavenger receptor class B type I mediates biliary cholesterol secretion independent ofATP-binding cassette transporter g5/g8 in mice. Hepatology 2009;50:1263-1272
55. Nofer JR, van Der Giet M, Tolle M, Wolinska I, von Wnuck Lipinski K, Baba HA, Tietge UJ, Godecke A, Ishii I, Kleuser B, Schafers M, Fobker M, ZidekW, Assmann G, ChunJ, Levkau B.HDLinduces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest 2004;113:569-581
56. DrewBG, Fidge NH, Gallon-Beaumier G, Kemp BE, Kingwell BA. High-density lipoprotein and apolipoprotein AI increase endothelial NO synthase activity by protein association and multisite phosphorylation. Proc Natl Acad Sci USA 2004;101:6999-7004
57. Mineo C, Deguchi H, Griffin JH, Shaul PW. Endothelial and antithrombotic actions of HDL. Circ Res 2006;98:1352-1364
58. Beitz J, ForsterW. Influence of human low density and high density lipoprotein cholesterol on the in vitro prostaglandin I2 synthetase activity. Biochim Biophys Acta 1980;620: 352-355
59. Norata GD, Callegari E, Inoue H, Catapano AL. HDL3 induces cyclooxygenase-2 expression and prostacyclin release in human endothelial cells via a p38 MAPK/CREdependent pathway: Effects on COX-2/PGI-synthase coupling. Arterioscler Thromb Vasc Biol 2004;24:871-877
60. Movva R, Rader DJ. Laboratory assessment of HDL heterogeneity and function. Clin Chem 2008;54:788-800
61. Saddar S, Yuhanna IS, Mineo C, Shaul PW. Abstract 1275: Mutations in the C-terminal transmembrane domain of scavenger receptor Class B Type I (SR-BI) selectively inhibit the cholesterol sensing that is required for HDL-initiated intracellular signaling. Circulation 2009;120:S469
62. Yuhanna IS, Zhu Y, Cox BE, Hahner LD, Osborne-Lawrence S, Lu P, Marcel YL, Anderson RG, Mendelsohn ME, Hobbs HH, Shaul PW. High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase. Nat Med 2001;7:853-857
63. Li XA, Titlow WB, Jackson BA, Giltiay N, Nikolova-Karakashian M, Uittenbogaard A, Smart EJ. High density lipoprotein binding to scavenger receptor, Class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner. J Biol Chem 2002;277:11058-11063
64. Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, Pagler T, Li R, Welch CL, Goldberg IJ, Tall AR. ABCG1 and HDL protect against endothelial dysfunction in mice fed a high-cholesterol diet. J Clin Invest 2008;118:3701-3713
65. Van Linthout S, Spillmann F, Lorenz M, Meloni M, Jacobs F, Egorova M, Stangl V, De Geest B, Schultheiss HP, Tschope C. Vascular-protective effects of high-density lipoprotein include the downregulation of the angiotensin II type 1 receptor. Hypertension 2009;53:682-687
66. Negre-Salvayre A, Dousset N, Ferretti G, Bacchetti T, Curatola G, Salvayre R. Antioxidant and cytoprotective properties of high-density lipoproteins in vascular cells. Free Radic Biol Med 2006;41:1031-1040
67. Terasaka N, Wang N, Yvan-Charvet L, Tall AR. High-density lipoprotein protects macrophages from oxidized low-density lipoprotein-induced apoptosis by promoting efflux of 7-ketocholesterol via ABCG1. Proc Natl Acad Sci USA 2007;104:15093-15098
68. Speidel MT, Booyse FM, Abrams A, Moore MA, Chung BH. Lipolyzed hypertriglyceridemic serum and triglyceride-rich lipoprotein cause lipid accumulation in and are cytotoxic to cultured human endothelial cells. High density lipoproteins inhibit this cytotoxicity. Thromb Res 1990;58:251-264
69. Sugano M, Tsuchida K, Makino N. High-density lipoproteins protect endothelial cells from tumor necrosis factor-Alpha-induced apoptosis. Biochem Biophys Res Commun 2000;272:872-876
70. Hamilton KK, Zhao J, Sims PJ. Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9. J Biol Chem 1993;268:3632-3638
71. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, von Eckardstein A, Seedorf U, Assmann G. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-Associated lysosphingolipids. J Biol Chem 2001;276:34480-34485
72. Yvan-Charvet L, Pagler TA, Seimon TA, Thorp E, Welch CL, Witztum JL, Tabas I, Tall AR. ABCA1 and ABCG1 protect against oxidative stress-induced macrophage apoptosis during efferocytosis. Circ Res 2010;106:1861-1869
73. Suc I, Escargueil-Blanc I, Troly M, Salvayre R, Negre-SalvayreA.HDLand ApoAprevent cell death of endothelial cells induced by oxidized LDL. Arterioscler Thromb Vasc Biol 1997;17:2158-2166
74. Robbesyn F, GarciaV, Auge N, Vieira O, FrisachMF, Salvayre R, Negre-SalvayreA.HDL counterbalance the proinflammatory effect of oxidized LDL by inhibiting intracellular reactive oxygen species rise, proteasome activation, and subsequent NF-kappaB activation in smooth muscle cells. FASEB J 2003;17:743-745
75. De Souza JA, VindisC, Negre-Salvayre A, Rye KA, Couturier M, Therond P, Chantepie S, Salvayre R, Chapman MJ, Kontush A. Small, dense HDL 3 particles attenuate apoptosis in endothelial cells: Pivotal role of apolipoprotein A-I. J Cell Mol Med 2010;14:608-620
76. Mineo C, ShaulPW.HDLstimulation of endothelial nitric oxide synthase: A novel mechanism of HDL action. Trends Cardiovasc Med 2003;13:226-231
77. UittenbogaardA, ShaulPW, Yuhanna IS, Blair A, Smart EJ. High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae. J Biol Chem 2000;275:11278-11283
78. Babitt J, Trigatti B, Rigotti A, Smart EJ, Anderson RG, Xu S, Krieger M. Murine SR-BI, a high density lipoprotein receptor that mediates selective lipid uptake, is N-glycosylated and fatty acylated and colocalizes with plasma membrane caveolae. J Biol Chem 1997; 272:13242-13249
79. Ortiz-Munoz G, Houard X, Martin-Ventura JL, Ishida BY, Loyau S, Rossignol P, Moreno JA, Kane JP, Chalkley RJ, Burlingame AL, Michel JB, Meilhac O.HDLantielastase activity prevents smooth muscle cell anoikis, a potential new antiatherogenic property. FASEB J 2009;23:3129-3139
80. Vaisar T, Pennathur S, Green PS, Gharib SA, Hoofnagle AN, Cheung MC, Byun J, Vuletic S, Kassim S, Singh P, Chea H, Knopp RH, Brunzell J, Geary R, Chait A, Zhao XQ, Elkon K, Marcovina S, Ridker P, Oram JF, Heinecke JW. Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDL. J Clin Invest 2007;117:746-756
81. Barter PJ, Nicholls S, Rye KA, AnantharamaiahGM,Navab M, FogelmanAM. Antiinflammatory properties of HDL. Circ Res 2004;95:764-772
82. Murphy AJ, Chin-Dusting JP, Sviridov D,Woollard KJ. The anti inflammatory effects of high density lipoproteins. Curr Med Chem 2009;16:667-675
83. Wang SH, Yuan SG, Peng DQ, Zhao SP. High-density lipoprotein affects antigen presentation by interfering with lipid raft: A promising anti-Atherogenic strategy. Clin Exp Immunol 2010;160:137-142
84. Saemann MD, Poglitsch M, Kopecky C, Haidinger M, Horl WH,Weichhart T. The versatility of HDL: A crucial anti-inflammatory regulator. Eur J Clin Invest 2010;40: 1131-1143
85. Shaw JA, Bobik A, Murphy A, Kanellakis P, Blombery P, Mukhamedova N,Woollard K, Lyon S, Sviridov D, Dart AM. Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque. Circ Res 2008;103:1084-1091
86. van Leuven SI, Birjmohun RS, Franssen R, Bisoendial RJ, De Kort H, Levels JH, Basser RL, Meijers JC, Kuivenhoven JA, Kastelein JJ, Stroes ES.ApoAI-phosphatidylcholine infusion neutralizes the atherothrombotic effects of C-reactive protein in humans. J Thromb Haemost 2009;7:347-354
87. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 1995;15:1987-1994
88. Calabresi L, Franceschini G, Sirtori CR, De Palma A, Saresella M, Ferrante P, Taramelli D. Inhibition of VCAM-1 expression in endothelial cells by reconstituted high density lipoproteins. Biochem Biophys Res Commun 1997;238:61-65
89. BakerPW, RyeKA, Gamble JR, VadasMA, Barter PJ. Ability of reconstituted high density lipoproteins to inhibit cytokine-induced expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. J Lipid Res 1999;40:345-353
90. Bursill CA, Castro ML, Beattie DT, Nakhla S, van Der Vorst E, Heather AK, Barter PJ, Rye K-A. High-density lipoproteins suppress chemokines and chemokine receptors in vitro and in vivo. Arterioscler Thromb Vasc Biol 2010;30:1773-1778
91. DrewBG, Duffy SJ, Formosa MF, Natoli AK, Henstridge DC, Penfold SA, Thomas WG, Mukhamedova N, De Courten B, Forbes JM, Yap FY, Kaye DM, van Hall G, Febbraio MA, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. Circulation 2009;119: 2103-2111
92. Drew BG, Duffy SJ, Forbes JM, Chin-Dusting J, Kaye DM, Kemp BE, Sviridov D, Steinberg GR, Kingwell BA. Abstract 1273: High density lipoprotein modulates glucose metabolism by multiple mechanisms. Circulation 2009;120:S468-S469
93. Yvan-Charvet L, Pagler T, Gautier E, Avagyan S, Siry R, SnoeckH, Randolph G, Tall AR. Abstract 5816: The human Apoa-1 transgene suppresses myeloid proliferation and accelerated atherosclerosis in Ldlr deficient mice reconstituted with ABC transporter deficient bone marrow. Circulation 2009;120:S1154
94. Yu BL,Wang SH, PengDQ, Zhao SP.HDLand immunomodulation: An emerging role of HDL against atherosclerosis. Immunol Cell Biol 2010;88:285-290
95. Hyka N, Dayer JM, Modoux C, Kohno T, Edwards CK III, Roux-Lombard P, Burger D. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-Alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001;97:2381-2389
96. Gruaz L, Delucinge-Vivier C, Descombes P, Dayer JM, Burger D. Blockade of T cell contact-Activation of human monocytes by high-density lipoproteins reveals a new pattern of cytokine and inflammatory genes. PLoS One 2010;5:e9418
97. Burger D, Dayer JM. High-density lipoprotein-Associated apolipoprotein A-I: The missing link between infection and chronic inflammation?. Autoimmun Rev 2002;1: 111-117
98. Pagler TA, Wang M, Mondal M, Murphy AJ, Westerterp M, Moore KJ, Maxfield FR, Tall AR. Deletion of ABCA1 and ABCG1 impairs macrophage migration because of increased Rac1 signaling. Circ Res 2011;108:194-200
99. Liao XL, Lou B, Ma J,WuMP. Neutrophils activation can be diminished by apolipoprotein A-I. Life Sci 2005;77:325-335
100. Murphy AJ, Suhartoyo A, ShawJ,Woollard K, Sviridov D,Chin-Dusting J. Abstract 5869: HDL and ApoA-I attenuate neutrophil activation in vitro and in vivo models of inflammation: A role for lipid rafts. Circulation 2009;120:S1166
101. Murphy AJ,Woollard KJ, Hoang A, Mukhamedova N, Stirzaker RA, McCormick SPA, Remaley AT, Sviridov D, Chin-Dusting J. High-density lipoprotein reduces the human monocyte inflammatory response. Arterioscler Thromb Vasc Biol 2008;28:2071-2077
102. Yvan-Charvet L,Welch C, Pagler TA, Ranalletta M, Lamkanfi M, Han S, IshibashiM, Li R, Wang N, Tall AR. Increased inflammatory gene expression in ABC transporterdeficient macrophages: Free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions. Circulation 2008;118: 1837-1847
103. Zhu X, Owen JS, Wilson MD, Li H, Griffiths GL, Thomas MJ, Hiltbold EM, Fessler MB, Parks JS. MacrophageABCA1reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res 2010;51:3196-3206
104. Umemoto T, Han CY, Mitra P, Averill MM, Tang C, Goodspeed L, Omer M, Subramanian S,Wang S,DenHartigh LJ,WeiH, Kim EJ, Kim J, OBrienKD, Chait A. Apolipoprotein AI and high-density lipoprotein have anti-inflammatory effects on adipocytes via cholesterol transporters: ATP-binding cassette A-1, ATP-binding cassette G-1, and scavenger receptor B-1. Circ Res 2013;112:1345-1354
105. Tang C, Liu Y, Kessler PS, Vaughan AM, OramJF. The macrophage cholesterol exporter ABCA1 functions as an anti-inflammatory receptor. J Biol Chem 2009;284: 32336-32343
106. De Nardo D, Labzin LI, Kono H, Seki R, Schmidt SV, Beyer M, Xu D, Zimmer S, Lahrmann C, Schildberg FA, Vogelhuber J, Kraut M, Ulas T, Kerksiek A, Krebs W, Bode N, Grebe A, Fitzgerald ML, Hernandez NJ, Williams BR, Knolle P, Kneilling M, Rocken M, Lutjohann D, Wright SD, Schultze JL, Latz E. High-density lipoprotein mediates anti-inflammatory reprogramming of macrophages via the transcriptional regulator ATF3. Nat Immunol 2014;15:152-160
107. Robbesyn F, Salvayre R, Negre-SalvayreA. Dual role of oxidized LDLon the NF-kappaB signaling pathway. Free Radic Res 2004;38:541-551
108. Xia P, Vadas MA, Rye KA, Barter PJ, Gamble JR. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem 1999;274:33143-33147
109. McGrath KC, Li XH, Puranik R, Liong EC, Tan JT, Dy VM, DiBartolo BA, Barter PJ, Rye KA, Heather AK. Role of 3beta-hydroxysteroid-delta 24 reductase in mediating antiinflammatory effects of high-density lipoproteins in endothelial cells. Arterioscler Thromb Vasc Biol 2009;29:877-882
110. Norata GD, Callegari E, Marchesi M, Chiesa G, Eriksson P, Catapano AL. High-density lipoproteins induce transforming growth factor-beta 2 expression in endothelial cells. Circulation 2005;111:2805-2811
111. Stocker R, Keaney JF Jr. Role of oxidative modifications in atherosclerosis. Physiol Rev 2004;84:1381-1478
112. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: Update and therapeutic implications. Circulation 2007;116: 1832-1844
113. Zerrad-Saadi A, Therond P, Chantepie S, Couturier M, Rye K-A, Chapman MJ, Kontush A. HDL3-Mediated inactivation of LDL-Associated phospholipid hydroperoxides is determined by the redox status of apolipoprotein A-I and HDL particle surface lipid rigidity: Relevance to inflammation and atherogenesis. Arterioscler Thromb Vasc Biol 2009;29:2169-2175
114. Kontush A, Chapman MJ. Antiatherogenic function of HDL particle subpopulations: Focus on antioxidative activities. Curr Opin Lipidol 2010;21:312-318
115. Sattler W, Christison J, Stocker R. Cholesterylester hydroperoxide reducing activity associated with isolated high- and low-density lipoproteins. Free Radic Biol Med 1995; 18:421-429
116. Christison JK, Rye KA, Stocker R. Exchange of oxidized cholesteryl linoleate between LDL and HDL mediated by cholesteryl ester transfer protein. J. Lipid Res 1995;36: 2017-2026
117. Garner B, Witting PK,Waldeck AR, Christison JK, Raftery M, Stocker R. Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol. J Biol Chem 1998;273:6080-6087
118. Garner B,Waldeck AR, Witting PK, Rye KA, Stocker R. Oxidation of high density lipoproteins. II. Evidence for direct reduction of lipid hydroperoxides by methionine residues of apolipoproteins AI and AII. J Biol Chem 1998;273:6088-6095
119. Van Lenten BJ, Navab M, Shih D, Fogelman AM, Lusis AJ. The role of high-density lipoproteins in oxidation and inflammation. Trends Cardiovasc Med 2001;11:155-161
120. BowryVW, Stanley KK, Stocker R. High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors. Proc Natl Acad Sci USA 1992;89:10316-10320
121. Proudfoot JM, Barden AE, Loke WM, Croft KD, Puddey IB, Mori TA. HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J. Lipid Res 2009;50:716-722
122. Christison J, Karjalainen A, Brauman J, Bygrave F, Stocker R. Rapid reduction and removal of HDL- but not LDL-Associated cholesteryl ester hydroperoxides by rat liver perfused in situ. Biochem J 1996;314:739-742
123. Tabet F, Lambert G, Cuesta Torres LF, Hou L, Sotirchos I, Touyz RM, Jenkins AJ, Barter PJ, Rye K-A. Lipid-free apolipoprotein A-I and discoidal reconstituted highdensity lipoprotein differentially inhibit glucose-induced oxidative stress in human macrophages. Arterioscler Thromb Vasc Biol 2011;31:1192-1200
124. Nicholls SJ, Dusting GJ,Cutri B, Bao S,DrummondGR, RyeKA, Barter PJ. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005;111:1543-1550
125. Pajkrt D, Doran JE, Koster F, Lerch PG, Arnet B, van Der Poll T, ten Cate JW, van Deventer SJ. Antiinflammatory effects of reconstituted high-density lipoprotein during human endotoxemia. J Exp Med 1996;184:1601-1608
126. Levels JH, Abraham PR, van Den Ende A, van Deventer SJ. Distribution and kinetics of lipoprotein-bound endotoxin. Infect Immun 2001;69:2821-2828
127. Stoll LL, Denning GM,Weintraub NL. Potential role of endotoxin as a proinflammatory mediator of atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24:2227-2236
128. WuA, Hinds CJ, Thiemermann C. High-density lipoproteins in sepsis and septic shock: Metabolism, actions, and therapeutic applications. Shock 2004;21:210-221
129. Levels JH, Pajkrt D, Schultz M, Hoek FJ, van Tol A, Meijers JC, van Deventer SJ. Alterations in lipoprotein homeostasis during human experimental endotoxemia and clinical sepsis. Biochim Biophys Acta 2007;1771:1429-1438
130. Wurfel MM, Kunitake ST, Lichenstein H, Kane JP, Wright SD. Lipopolysaccharide (LPS)-binding protein is carried on lipoproteins and acts as a cofactor in the neutralization of LPS. J Exp Med 1994;180:1025-1035
131. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci USA 1993;90: 12040-12044
132. Hajduk SL, Moore DR, Vasudevacharya J, Siqueira H, Torri AF, Tytler EM, Esko JD. Lysis of Trypanosoma brucei by a toxic subspecies of human high density lipoprotein. J Biol Chem 1989;264:5210-5217
133. Pays E, Vanhollebeke B, Vanhamme L, Paturiaux-Hanocq F, Nolan DP, Perez-Morga D. The trypanolytic factor of human serum. Nat Rev Microbiol 2006;4:477-486
134. Perez-Morga D, Vanhollebeke B, Paturiaux-Hanocq F, Nolan DP, Lins L, Homble F, Vanhamme L, Tebabi P, Pays A, Poelvoorde P, Jacquet A, Brasseur R, Pays E. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005;309:469-472
135. Lecordier L, Vanhollebeke B, Poelvoorde P, Tebabi P, Paturiaux-Hanocq F, Andris F, Lins L, Pays E. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 2009;5:e1000685
136. von Eckardstein A, Sibler RA. Possible contributions of lipoproteins and cholesterol to the pathogenesis of diabetes mellitus type 2. Curr Opin Lipidol 2011;22:26-32
137. Fryirs MA, Barter PJ, Appavoo M, Tuch BE, Tabet F, Heather AK, Rye K-A. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion. Arterioscler Thromb Vasc Biol 2010;30:1642-1648
138. Rutti S, Ehses JA, Sibler RA, Prazak R, Rohrer L, Georgopoulos S, MeierDT, Niclauss N, BerneyT, DonathMY, von Eckardstein A. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic betacells. Endocrinology 2009;150:4521-4530
139. Petremand J, Bulat N, ButtyAC, Poussin C, Rutti S,AuK, Ghosh S, MooserV, Thorens B, Yang JY, Widmann C,Waeber G. Involvement of 4E-BP1 in the protection induced by HDLs on pancreatic beta-cells. Mol Endocrinol 2009;23:1572-1586
140. Dalla-Riva J, Stenkula KG, Petrlova J, Lagerstedt JO. Discoidal HDL and apoA-I-derived peptides improve glucose uptake in skeletal muscle. J Lipid Res 2013;54:1275-1282
141. Calkin AC, Drew BG, Ono A, Duffy SJ, Gordon MV, Schoenwaelder SM, Sviridov D, Cooper ME, Kingwell BA, Jackson SP. Reconstituted high-density lipoprotein attenuates platelet function in individuals with type 2 diabetes mellitus by promoting cholesterol efflux. Circulation 2009;120:2095-2104
142. Lerch PG, Spycher MO, Doran JE. Reconstituted high density lipoprotein (rHDL) modulates platelet activity in vitro and ex vivo. Thromb Haemost 1998;80:316-320
143. Nofer JR, Walter M, Kehrel B, Wierwille S, Tepel M, Seedorf U, Assmann G. HDL3-mediated inhibition of thrombin-induced platelet aggregation and fibrinogen binding occurs via decreased production of phosphoinositide-derived second messengers 1,2-diacylglycerol and inositol 1,4,5-tris-phosphate. Arterioscler Thromb Vasc Biol 1998;18:861-869
144. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: From bench to bedside. Arterioscler Thromb Vasc Biol 2003;23:1724-1731
145. Higashihara M, Kinoshita M, Kume S, Teramoto T, Kurokawa K. Inhibition of platelet function by high-density lipoprotein from a patient with apolipoprotein E deficiency. Biochem Biophys Res Commun 1991;181:1331-1336
146. Beitz J, Beitz A, Muller G, Giessler C, Mest HJ. Influence of HDL on the formation of 6-keto-PGF1 alpha and TXB2 in vitro: The importance of the source of HDL. Eicosanoids 1992;5:53-56
147. Surya II, Gorter G, AkkermanJW. Arachidonate transfer between platelets and lipoproteins. Thromb Haemost 1992;68:719-726
148. Fujimoto Y, Tsunomori M, Muta E, Yamamoto T, Nishida H, Sakuma S, Fujita T. High density lipoprotein inhibits platelet 12-lipoxygenase activity. Res Commun Mol Pathol Pharmacol 1994;85:355-358
149. HolyEW, Besler C, Landmesser U, Luscher TF, Tanner FC. Abstract 5486: High density lipoprotein (HDL) from healthy subjects, but not from patients with coronary artery disease, exerts anti-thrombotic effects on human endothelial cells. Circulation 2009; 120:S1100
150. Chen LY, Mehta JL. Inhibitory effect of high-density lipoprotein on platelet function is mediated by increase in nitric oxide synthase activity in platelets. Life Sciences 1994; 55:1815-1821
151. Nofer JR, BroddeMF, Kehrel BE. High-density lipoproteins, platelets and the pathogenesis of atherosclerosis. Clin Exp Pharmacol Physiol 2010;37:726-735
152. Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. MicroRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011;13:423-433
153. Wagner J, Riwanto M, Besler C, Knau A, Fichtlscherer S, Roxe T, Zeiher AM, Landmesser U, Dimmeler S. Characterization of levels and cellular transfer of circulating lipoprotein-bound microRNAs. Arterioscler Thromb Vasc Biol 2013;33:1392-1400
154. Chen WJ, Zhang M, Zhao GJ, Fu Y, ZhangDW, Zhu HB, Tang CK. MicroRNA-33 in atherosclerosis etiology and pathophysiology. Atherosclerosis 2013;227:201-208
155. Rayner KJ, Moore KJ. MicroRNA control of high-density lipoprotein metabolism and function. Circ Res 2014;114:183-192
156. Rayner KJ, Suarez Y, Davalos A, Parathath S, Fitzgerald ML, Tamehiro N, Fisher EA, MooreKJ, Fernandez-Hernando C. MiR-33 contributes to the regulation of cholesterol homeostasis. Science 2010;328:1570-1573
157. Hu YW,Wang Q, Ma X, Li XX, Liu XH, Xiao J, Liao DF, Xiang J, Tang CK. TGF-beta1 up-regulates expression of ABCA1, ABCG1 and SR-BI through liver×receptor alpha signaling pathway in THP-1 macrophage-derived foam cells. J Atheroscler Thromb 2010; 17:493-502
158. Fernandez-Hernando C, Suarez Y, Rayner KJ, Moore KJ. MicroRNAs in lipid metabolism. Curr Opin Lipidol 2011;22:86-92
159. Najafi-Shoushtari SH, Kristo F, Li Y, Shioda T, Cohen DE, Gerszten RE, Naar AM. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010;328:1566-1569
160. Horie T,OnoK, Horiguchi M, Nishi H, NakamuraT, Nagao K, Kinoshita M, KuwabaraY, Marusawa H, Iwanaga Y, Hasegawa K, Yokode M, Kimura T, Kita T. MicroRNA-33 encoded by an intron of sterol regulatory element-binding protein 2 (Srebp2) regulates HDL in vivo. Proc Natl Acad Sci USA 2010;107:17321-17326
161. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, van Gils JM, Rayner AJ, Chang AN, Suarez Y, Fernandez-Hernando C, Fisher EA, Moore KJ. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest 2011;121:2921-2931
162. Horie T, Baba O, Kuwabara Y, Chujo Y, Watanabe S, Kinoshita M, Horiguchi M, Nakamura T, Chonabayashi K, Hishizawa M, Hasegawa K, Kume N, Yokode M, Kita T, Kimura T, Ono K. MicroRNA-33 deficiency reduces the progression of atherosclerotic plaque in ApoE-/- mice. J Am Heart Assoc 2012;1:e003376
163. Dietschy JM, Turley SD. Thematic reviewseries: Brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375-1397
164. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimers disease. Brain Res Brain Res Rev 1998;27:119-142
165. Kontush A. Apolipoprotein Abeta: Black sheep in a good family. Brain Pathol 2004;14: 433-447
166. Illingworth DR, Glover J. The composition of lipids in cerebrospinal fluid of children and adults. J.Neurochem 1971;18:769-776
167. Koch S, Donarski N, Goetze K, Kreckel M, Stuerenburg HJ, Buhmann C, Beisiegel U. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-1151
168. Song H, Saito K, Seishima M,NomaA, Urakami K, Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimers disease. Neurosci Lett 1997;231:175-178
169. Demeester N, Castro G, Desrumaux C, De Geitere C, Fruchart JC, Santens P, Mulleners E, Engelborghs S, De Deyn PP, Vandekerckhove J, Rosseneu M, Labeur C. Characterization and functional studies of lipoproteins, lipid transfer proteins, and lecithin:cholesterol acyltransferase in CSF of normal individuals and patients with Alzheimers disease. J Lipid Res 2000;41:963-974
170. Pfrieger FW. Outsourcing in the brain: Do neurons depend on cholesterol delivery by astrocytes?. Bioessays 2003;25:72-78
171. Yu C, Youmans KL, LaDu MJ. Proposed mechanism for lipoprotein remodelling in the brain. Biochim Biophys Acta 2010;1801:819-823
172. Vance JE, Hayashi H. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim Biophys Acta 2010;1801:806-818
173. Holtzman DM, Herz J, Bu G. Apolipoprotein E and apolipoprotein E receptors: Normal biology and roles in Alzheimer disease. Cold Spring Harb Perspect Med 2012;2:a006312
174. Davidson WS, Silva RA, Chantepie S, Lagor WR, Chapman MJ, Kontush A. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: Relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009;29:870-876
175. Heinecke JW. The HDL proteome: A marker - and perhaps mediator - of coronary artery disease. J. Lipid Res 2009;50:S167-S171
176. Gordon S, Durairaj A, Lu JL, Davidson WS. High-density lipoprotein proteomics: Identifying new drug targets and biomarkers by understanding functionality. Curr Cardiovasc Risk Rep 2010;4:1-8
177. Gordon SM, Deng J, Lu LJ, Davidson WS. Proteomic characterization of human plasma high density lipoprotein fractionated by gel filtration chromatography. J Proteome Res 2010;9:5239-5249
178. Camont L, LhommeM, Rached F, Le GoffW, Negre-Salvayre A, Salvayre R, Calzada C, Lagarde M, Chapman MJ, Kontush A. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: Relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol 2013;33:2715-2723
179. Shah AS, Tan L, Long JL, Davidson WS. Proteomic diversity of high density lipoproteins: Our emerging understanding of its importance in lipid transport and beyond. J Lipid Res 2013;54:2575-2585
180. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?. Nat Clin Pract Cardiovasc Med 2006;3:144-153
181. Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med 2011;17:594-603
182. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P. Antiatherogenic functionality of high density lipoprotein: How much versus how good. J Atheroscler Thromb 2008;15:52-62